Certis Oncology Awarded AAALAC Accreditation
Certis Oncology Solutions, a precision oncology and translational science company, announced that it has been awarded accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International). This voluntary and internationally recognized accreditation reflects the company’s commitment to go beyond standards required by regulatory agencies to achieve excellence in animal care and use.
“This is another important milestone for Certis, said CEO, Peter Ellman. “Securing AAALAC accreditation signals to pharmaceutical clients that we are a mature partner with robust and scalable quality systems, and that we are committed to animal use best practices.”
Certis provides high-precision translational drug discovery and development services to therapeutics innovators. Since the launch of its pharmaceutical services offering 18 months ago, the company has partnered with more than 50 oncology-focused drug developers. Unlike most preclinical contract research organizations (CROs), Certis has a precision medicine focus, and also has received CLIA certification from the Centers for Medicare & Medicaid Services—an accreditation that enables the company to accept human biological specimens for diagnostic testing.
“Our direct connection to the clinic is an important differentiator for Certis,” said Ellman. “It not only allows us to provide functional precision oncology directly to patients, our CLIA status facilitates the conduct of co-clinical trials, which employ mouse avatars of patients enrolled in trials to expedite clinical development.”
To receive AAALAC International accreditation, an institution must submit a detailed program description that details all aspects of its animal care and use. Once the program description is reviewed, AAALAC International conducts a comprehensive, onsite assessment of the program and facilities to determine if the institution will be awarded accreditation.
Certis Oncology Solutions